

Freedom of Information Request

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following two questions.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)-	3
• Abemaciclib + Fulvestrant- 8 patients	
• Anthracycline (e.g. doxorubicin or epirubicin) as a single agent- Atezolizumab +Nab-paclitaxel/Paclitaxel-	0 0
• Capecitabine as a single agent-	11
• Eribulin as a single agent or in combination-	1
• Everolimus + Exemestane-	0
• Fulvestrant as a single agent-	9
• Lapatinib-	0
• Neratinib –	2
• Parp Inhibitors (Olaparib/Talazoparib)-	0
• Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)-	28
• Palbociclib + Fulvestrant-	4
• Pembrolizumab-	0
• Platinum (e.g. carboplatin or cisplatin) as a single agent-	0
• Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)-	0
• Ribociclib + Fulvestrant-	0
• Sacituzumab Govitecan-	1
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent-	48
• Taxane and/or Anthracycline in combination-	37
• Trastuzumab as a single agent or in combination-	41
• Trastuzumab emtansine-	5
• Transtuzumab deruxtecan-	2
• Any other active systemic anti-cancer therapy-	11

Q2. In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with:

• Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)-	0
• Taxane and/or Anthracycline (monotherapy or in combination)-	56
• Any other active systemic anti-cancer therapy-	93